Compound ID | 1353
Class: Beta-lactam + beta-lactamase inhibitor
| Agent Type: | Semisynthetic; Synthetic; Small molecule; Direct acting; Antibiotic adjuvant; |
| Spectrum of activity: | Gram-positive & Gram-negative |
| Mechanism of action: | Cell wall synthesis inhibitor. In combination with a beta-lactamase inhibitor |
| Institute where first reported: | Novartis |
| Highest development stage: | Preclinical |
| Development status: | Experimental |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/140855264 |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/43672 |
| Citation: | https://academic.oup.com/jac/article-abstract/75/6/1530/5766087?redirectedFrom=fulltext |